Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Impact of aging and caloric restriction on fibroblast growth factor 21 signaling in rat white adipose tissue.

Fujii N, Uta S, Kobayashi M, Sato T, Okita N, Higami Y.

Exp Gerontol. 2019 Apr;118:55-64. doi: 10.1016/j.exger.2019.01.001. Epub 2019 Jan 5.

2.

Differential Metabolic Responses to Adipose Atrophy Associated with Cancer Cachexia and Caloric Restriction in Rats and the Effect of Rikkunshito in Cancer Cachexia.

Sudo Y, Otsuka H, Miyakawa R, Goto A, Kashiwase Y, Terawaki K, Miyano K, Hirao Y, Taki K, Tagawa R, Kobayashi M, Okita N, Uezono Y, Higami Y.

Int J Mol Sci. 2018 Dec 3;19(12). pii: E3852. doi: 10.3390/ijms19123852.

3.

Identification of WWP1 as an obesity-associated E3 ubiquitin ligase with a protective role against oxidative stress in adipocytes.

Kobayashi M, Hoshino S, Abe T, Okita N, Tagawa R, Nagai W, Konno R, Suzuki Y, Furuya K, Ishikawa N, Okado H, Oku M, Iwamoto M, Miura Y, Sudo Y, Higami Y.

Biochem Biophys Res Commun. 2019 Jan 1;508(1):117-122. doi: 10.1016/j.bbrc.2018.11.127. Epub 2018 Nov 22.

4.

Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.

Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N.

Invest New Drugs. 2018 Sep 28. doi: 10.1007/s10637-018-0669-7. [Epub ahead of print]

PMID:
30267338
5.

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.

Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJA, de Gramont A, Tournigand C, Zeuzem S, Trojan J.

Oncotarget. 2017 Dec 20;9(12):10272-10283. doi: 10.18632/oncotarget.23475. eCollection 2018 Feb 13.

6.

Taurine is an amino acid with the ability to activate autophagy in adipocytes.

Kaneko H, Kobayashi M, Mizunoe Y, Yoshida M, Yasukawa H, Hoshino S, Itagawa R, Furuichi T, Okita N, Sudo Y, Imae M, Higami Y.

Amino Acids. 2018 May;50(5):527-535. doi: 10.1007/s00726-018-2550-6. Epub 2018 Mar 9.

PMID:
29523960
7.

Differential response to caloric restriction of retroperitoneal, epididymal, and subcutaneous adipose tissue depots in rats.

Narita T, Kobayashi M, Itakura K, Itagawa R, Kabaya R, Sudo Y, Okita N, Higami Y.

Exp Gerontol. 2018 Apr;104:127-137. doi: 10.1016/j.exger.2018.01.016. Epub 2018 Feb 2.

8.

A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.

Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N.

Int J Clin Oncol. 2018 Jun;23(3):466-472. doi: 10.1007/s10147-018-1239-x. Epub 2018 Jan 20.

PMID:
29353337
9.

Trehalose protects against oxidative stress by regulating the Keap1-Nrf2 and autophagy pathways.

Mizunoe Y, Kobayashi M, Sudo Y, Watanabe S, Yasukawa H, Natori D, Hoshino A, Negishi A, Okita N, Komatsu M, Higami Y.

Redox Biol. 2018 May;15:115-124. doi: 10.1016/j.redox.2017.09.007. Epub 2017 Sep 20.

10.

Mitochondrial intermediate peptidase is a novel regulator of sirtuin-3 activation by caloric restriction.

Kobayashi M, Takeda K, Narita T, Nagai K, Okita N, Sudo Y, Miura Y, Tsumoto H, Nakagawa Y, Shimano H, Higami Y.

FEBS Lett. 2017 Dec;591(24):4067-4073. doi: 10.1002/1873-3468.12914. Epub 2017 Nov 28.

11.

Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma.

Sudo K, Kato K, Kuwabara H, Sasaki Y, Takahashi N, Shoji H, Iwasa S, Honma Y, Okita NT, Takashima A, Hamaguchi T, Yamada Y, Ito Y, Itami J, Fukuda T, Tobinai K, Boku N.

Oncology. 2018;94(1):47-54. doi: 10.1159/000480515. Epub 2017 Oct 28.

PMID:
29080886
12.

Modified Western blotting for insulin and other diabetes-associated peptide hormones.

Okita N, Higami Y, Fukai F, Kobayashi M, Mitarai M, Sekiya T, Sasaki T.

Sci Rep. 2017 Jul 31;7(1):6949. doi: 10.1038/s41598-017-04456-4.

13.

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature.

Watanabe S, Takashima A, Taniguchi H, Tanaka Y, Nakamura S, Okita N, Honma Y, Iwasa S, Kato K, Hamaguchi T, Boku N.

Case Rep Oncol. 2017 May 5;10(2):407-415. doi: 10.1159/000474939. eCollection 2017 May-Aug.

14.

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.

Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group.

Neuroendocrinology. 2018;106(3):211-220. doi: 10.1159/000477585. Epub 2017 May 24.

PMID:
28554173
15.

[Comparison of Response to Chemotherapy between Ovarian and Extraovarian Metastasis of Gastric Cancer].

Ishimoto U, Nakamura S, Sasaki Y, Takahashi N, Iwasa S, Honma Y, Okita N, Takashima A, Kato K, Hamaguchi T, Boku N.

Gan To Kagaku Ryoho. 2017 Mar;44(3):233-237. Japanese.

PMID:
28292993
16.

Sterol regulatory element-binding protein-1c orchestrates metabolic remodeling of white adipose tissue by caloric restriction.

Fujii N, Narita T, Okita N, Kobayashi M, Furuta Y, Chujo Y, Sakai M, Yamada A, Takeda K, Konishi T, Sudo Y, Shimokawa I, Higami Y.

Aging Cell. 2017 Jun;16(3):508-517. doi: 10.1111/acel.12576. Epub 2017 Mar 3.

17.

Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry.

Nishiumi S, Kobayashi T, Kawana S, Unno Y, Sakai T, Okamoto K, Yamada Y, Sudo K, Yamaji T, Saito Y, Kanemitsu Y, Okita NT, Saito H, Tsugane S, Azuma T, Ojima N, Yoshida M.

Oncotarget. 2017 Mar 7;8(10):17115-17126. doi: 10.18632/oncotarget.15081.

18.

Involvement of lysosomal dysfunction in autophagosome accumulation and early pathologies in adipose tissue of obese mice.

Mizunoe Y, Sudo Y, Okita N, Hiraoka H, Mikami K, Narahara T, Negishi A, Yoshida M, Higashibata R, Watanabe S, Kaneko H, Natori D, Furuichi T, Yasukawa H, Kobayashi M, Higami Y.

Autophagy. 2017 Apr 3;13(4):642-653. doi: 10.1080/15548627.2016.1274850. Epub 2017 Jan 25.

19.

Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.

Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Boku N.

Gastric Cancer. 2017 Jul;20(4):655-662. doi: 10.1007/s10120-016-0670-9. Epub 2016 Nov 17.

PMID:
27858180
20.

Improved protocol for extraction of genomic DNA from formalin-fixed paraffin-embedded tissue samples without the use of xylene.

Kikuchi A, Sawamura T, Daimaru O, Horie M, Sasaki K, Okita N.

Clin Chem Lab Med. 2016 Dec 1;54(12):e375-e377. doi: 10.1515/cclm-2016-0108. No abstract available.

PMID:
27171389
21.

A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab.

Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, Honma Y, Okita NT, Takashima A, Hamaguchi T, Boku N, Shimada Y, Honda K, Yamada T, Yamada Y.

Cancer Chemother Pharmacol. 2016 Sep;78(3):567-75. doi: 10.1007/s00280-016-3111-x. Epub 2016 Jul 20.

PMID:
27438067
22.

Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.

Yamaguchi T, Iwasa S, Nagashima K, Ikezawa N, Hamaguchi T, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Yamada Y, Shimada Y.

Anticancer Res. 2016 Jul;36(7):3531-6.

PMID:
27354619
23.

Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.

Araki T, Takashima A, Hamaguchi T, Honma Y, Iwasa S, Okita N, Kato K, Yamada Y, Hashimoto H, Taniguchi H, Kushima R, Nakao K, Boku N, Shimada Y.

Anticancer Drugs. 2016 Sep;27(8):794-9. doi: 10.1097/CAD.0000000000000393.

PMID:
27341105
24.

Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.

Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T, Yamada Y.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1727-38. doi: 10.1007/s00432-016-2184-6. Epub 2016 Jun 2.

PMID:
27256004
25.

Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients.

Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T.

Cancer Immunol Res. 2016 Jul;4(7):592-9. doi: 10.1158/2326-6066.CIR-15-0298. Epub 2016 Apr 28.

26.

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies.

Takahashi N, Iwasa S, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Hamaguchi T, Shimada Y, Yamada Y.

Br J Cancer. 2016 Apr 26;114(9):1003-11. doi: 10.1038/bjc.2016.74. Epub 2016 Mar 22.

27.

Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.

Sasaki Y, Hamaguchi T, Yamada Y, Takahashi N, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Nagai Y, Taniguchi H, Boku N, Ushijima T, Shimada Y.

Asian Pac J Cancer Prev. 2016;17(2):539-43.

28.

Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.

Takahashi N, Furuta K, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y, Yamada Y.

Oncotarget. 2016 Jan 26;7(4):4925-38. doi: 10.18632/oncotarget.6753.

29.

Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.

Shoji H, Yamada Y, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y.

Anticancer Res. 2015 Sep;35(9):5055-61.

PMID:
26254407
30.

S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.

Iwasa S, Nagashima K, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Yasui H, Kato K, Okita NT, Shimada Y, Yamada Y.

Cancer Chemother Pharmacol. 2015 Sep;76(3):605-14. doi: 10.1007/s00280-015-2834-4. Epub 2015 Jul 29.

PMID:
26220845
31.

Japanese universal health care faces a crisis in cancer treatment.

Fujiwara Y, Yonemori K, Shibata T, Okita N, Ushirozawa N.

Lancet Oncol. 2015 Mar;16(3):251-2. doi: 10.1016/S1470-2045(15)70007-0. No abstract available.

PMID:
25752548
32.

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.

Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y.

Cancer Sci. 2015 May;106(5):604-10. doi: 10.1111/cas.12642. Epub 2015 Apr 29.

33.

Supplementation of strontium to a chondrogenic medium promotes chondrogenic differentiation of human dedifferentiated fat cells.

Okita N, Honda Y, Kishimoto N, Liao W, Azumi E, Hashimoto Y, Matsumoto N.

Tissue Eng Part A. 2015 May;21(9-10):1695-704. doi: 10.1089/ten.TEA.2014.0282. Epub 2015 Apr 15.

PMID:
25669848
34.

Chronological analysis of caloric restriction-induced alteration of fatty acid biosynthesis in white adipose tissue of rats.

Okita N, Tsuchiya T, Fukushima M, Itakura K, Yuguchi K, Narita T, Hashizume Y, Sudo Y, Chiba T, Shimokawa I, Higami Y.

Exp Gerontol. 2015 Mar;63:59-66. doi: 10.1016/j.exger.2015.01.043. Epub 2015 Jan 20.

PMID:
25616173
35.

A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.

Shirakawa T, Kato K, Nagashima K, Nishikawa A, Sawada R, Takahashi N, Shoji H, Sasaki Y, Honma Y, Iwasa S, Takashima A, Okita N, Hamaguchi T, Yamada Y, Shimada Y.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1207-15. doi: 10.1007/s00280-014-2597-3. Epub 2014 Sep 30.

PMID:
25267597
36.

The poly(adenosine diphosphate-ribose) polymerase inhibitor PJ34 reduces pulmonary ischemia-reperfusion injury in rats.

Hatachi G, Tsuchiya T, Miyazaki T, Matsumoto K, Yamasaki N, Okita N, Nanashima A, Higami Y, Nagayasu T.

Transplantation. 2014 Sep 27;98(6):618-24. doi: 10.1097/TP.0000000000000305.

37.

Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.

Okuma HS, Iwasa S, Shoji H, Takashima A, Okita N, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y.

Anticancer Res. 2014 Sep;34(9):5037-41.

PMID:
25202088
38.

Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.

Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y.

Cancer Sci. 2014 Aug;105(8):1002-7. doi: 10.1111/cas.12453. Epub 2014 Aug 7.

39.

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.

Hayashi H, Arao T, Matsumoto K, Kimura H, Togashi Y, Hirashima Y, Horita Y, Iwasa S, Okita NT, Honma Y, Takashima A, Kato K, Hamaguchi T, Shimada Y, Nakagawa K, Nishio K, Yamada Y.

Oncotarget. 2014 May 15;5(9):2588-95.

40.

Inhibitory effect of p53 on mitochondrial content and function during adipogenesis.

Okita N, Ishikawa N, Mizunoe Y, Oku M, Nagai W, Suzuki Y, Matsushima S, Mikami K, Okado H, Sasaki T, Higami Y.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):91-7. doi: 10.1016/j.bbrc.2014.02.059. Epub 2014 Feb 21.

PMID:
24565844
41.

Segmental motion of forefoot and hindfoot as a diagnostic tool.

Okita N, Meyers SA, Challis JH, Sharkey NA.

J Biomech. 2013 Oct 18;46(15):2578-85. doi: 10.1016/j.jbiomech.2013.08.014. Epub 2013 Sep 7.

42.

Midtarsal joint locking: new perspectives on an old paradigm.

Okita N, Meyers SA, Challis JH, Sharkey NA.

J Orthop Res. 2014 Jan;32(1):110-5. doi: 10.1002/jor.22477. Epub 2013 Sep 3.

43.

Catalytic micromotor generating self-propelled regular motion through random fluctuation.

Yamamoto D, Mukai A, Okita N, Yoshikawa K, Shioi A.

J Chem Phys. 2013 Jul 21;139(3):034705. doi: 10.1063/1.4813791.

44.

Experimental evidence supporting isometric functioning of the extrinsic toe flexors during gait.

Hofmann CL, Okita N, Sharkey NA.

Clin Biomech (Bristol, Avon). 2013 Jul;28(6):686-91. doi: 10.1016/j.clinbiomech.2013.05.006. Epub 2013 Jun 2.

PMID:
23735778
45.

In vitro human periodontal ligament-like tissue formation with porous poly-L-lactide matrix.

Liao W, Okada M, Sakamoto F, Okita N, Inami K, Nishiura A, Hashimoto Y, Matsumoto N.

Mater Sci Eng C Mater Biol Appl. 2013 Aug 1;33(6):3273-80. doi: 10.1016/j.msec.2013.04.008. Epub 2013 Apr 11.

PMID:
23706210
47.

CHK1 cleavage in programmed cell death is intricately regulated by both caspase and non-caspase family proteases.

Okita N, Yoshimura M, Watanabe K, Minato S, Kudo Y, Higami Y, Tanuma S.

Biochim Biophys Acta. 2013 Jan;1830(1):2204-13. doi: 10.1016/j.bbagen.2012.10.009. Epub 2012 Oct 16.

PMID:
23085068
48.

DNA damage-induced CHK1 autophosphorylation at Ser296 is regulated by an intramolecular mechanism.

Okita N, Minato S, Ohmi E, Tanuma S, Higami Y.

FEBS Lett. 2012 Nov 16;586(22):3974-9. doi: 10.1016/j.febslet.2012.09.048. Epub 2012 Oct 12.

49.

Autophagosomes accumulate in differentiated and hypertrophic adipocytes in a p53-independent manner.

Mikami K, Okita N, Tokunaga Y, Ichikawa T, Okazaki T, Takemoto K, Nagai W, Matsushima S, Higami Y.

Biochem Biophys Res Commun. 2012 Nov 2;427(4):758-63. doi: 10.1016/j.bbrc.2012.09.134. Epub 2012 Oct 4.

PMID:
23041188
50.

Caloric restriction-associated remodeling of rat white adipose tissue: effects on the growth hormone/insulin-like growth factor-1 axis, sterol regulatory element binding protein-1, and macrophage infiltration.

Chujo Y, Fujii N, Okita N, Konishi T, Narita T, Yamada A, Haruyama Y, Tashiro K, Chiba T, Shimokawa I, Higami Y.

Age (Dordr). 2013 Aug;35(4):1143-56. doi: 10.1007/s11357-012-9439-1. Epub 2012 May 28.

Supplemental Content

Support Center